Antonio Jimeno

Dr. Jimeno trained in Internal Medicine and Medical Oncology in Madrid, Spain, where he also obtained his Ph.D. in 2003. Then he continued his training with a Drug Development Clinical Fellowship at Johns Hopkins University (2003-2005), where he later was an Instructor of Oncology (2006-2008). Dr. Jimeno joined the UCSOM Faculty in April 2008 as an Assistant Professor of Medicine. In 2010 he became an Associate Professor and the Director of the Head and Neck Cancer Medical Oncology Program, as well as the Director of the Cancer Stem Cell directed Clinical Trials Program (a joint collaboration between the Gates Center for Stem Cell Biology and the University of Colorado Cancer Center). In 2014 he became a Professor of Medicine. He is also the Daniel and Janet Mordecai Endowed Chair for Cancer Stem Cell Research. Dr. Jimeno has an interest in integrating preclinical research, drug development, and clinical research in head and neck squamous cell cancers. His aim is to bridge the lab and the clinic by 1) developing direct patient xenograft models of head and neck and other cancers to generate better cancer models and as a platform to study cancer stem cells, 2) conducting preclinical tests of targeted agents against de-regulated pathways and cancer stem cells, and 3) devising ways to integrate that knowledge into clinical trials to individualize anti-cancer therapy. His concomitant work in the laboratory and the clinic has materialized in the form of novel inventions (drugs and biomarkers) that are currently the subject of prospective clinical testing. He has been recognized for his research efforts with an ASCO Young Investigator Award in 2005, and two ASCO Merit Awards in 2004 and 2006. He is the author of over 90 original research manuscripts, over 50 reviews, over 12 patents, and holds peer-review research from multiple organizations including the National Institutes of Health, and the Department of Defense. He is the Principal Investigator of over 25 clinical trials, both Phase 1 trials in patients with solid tumors, and Phase 1 and 2 studies for patients with head and neck squamous cell cancers.